Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has improved its financial position through recent equity financings and option exercises, resulting in a significant increase in financing income, rising to $284,000 for the quarter and $611,000 year-to-date from $144,000 last year. The company is preparing for its full market launch of the LIBERTY Endovascular Robotic System, enhancing its commercial and production capabilities by expanding its team and securing a partnership with a third-party logistics provider, which supports operational readiness. Additionally, the positive feedback from healthcare providers regarding the product underscores its market potential, suggesting a strong foundation for anticipated growth as the company plans to enter major markets in the coming years.

Bears say

Microbot Medical Inc faces significant risks that adversely impact its financial outlook, including delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into the cardiac and neurological markets. The company also grapples with reimbursement headwinds, lack of near-term profitability, and potential erosion of hospital margins due to the device's costs, which could hinder its adoption. Additionally, the absence of data from randomized controlled trials and setbacks in securing international regulatory approvals contribute to a challenging market environment, posing threats to the company's financial performance and growth trajectory.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.